Conference milestone

Personalised Cancer Vaccines Clear Phase III
Intismeran autogene plus pembrolizumab reduced melanoma recurrence or death by 42% in the first positive Phase III trial of an individualised mRNA neoantigen therapy. The science has crossed an important threshold. Manufacturing, reimbursement and equitable delivery now become part of the clinical question.

Energy drinks went mainstream before their cardiac safety evidence did

Cardiometabolic care is screening the pieces. It is not yet connecting them

Enhertu Stumbles in Early Breast Cancer

Endometrial Cancer Gets a Strong ADC Win

A filter can blunt pollution’s cardiac effects. It cannot be the policy

Cardiovascular risk in autoimmune disease begins before the risk calculator notices

Menopause before 40 should not be treated as a reproductive footnote

Skin Cancer AI Has Crossed a Line: It Is Discharging Patients on Its Own

Tirzepatide’s Next Question: What Lies Beyond Cardiovascular Events?
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
